The Filings Report

Johnson & Johnson

JNJNYSECIK 200406Healthcare / Drug Manufacturersfiscal year ends December73 quarters since 2008

Revenue, Q3 FY2026
$25.4B
+5.9% on Q3 FY2025
Net income
$210M
−95.9% on Q3 FY2025
Free cash flow
$6.4B
−20.6% on Q3 FY2025
Diluted EPS
$0.09
−95.8% on Q3 FY2025
Revenue, TTM
$99.3B
trailing four quarters
Net margin, TTM
16.2%
net income $16.1B
Free cash flow, TTM
$20.6B
$26.2B less $5.6B capex
Cash and equivalents
$16.9B
long-term debt $35.8B, Sep 27, 2026
Shares, 12-month change
−0.1%
2.41B shares, Sep 27, 2026
Buybacks, TTM
$7.9B
1.2% of market value
Dividends, TTM
—
no yield
Market value
$657.7B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 21, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 27, 2026, Johnson & Johnson reported revenue of $25.4B, +5.9% on Q3 FY2025, and net income of $210M (−95.9%). Free cash flow, operating cash flow less capital expenditures, was $6.4B ($7.7B less $1.4B). Diluted earnings per share were $0.09.

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 21, 2026.

Revenue and net incomeRevenueNet income
−$10B$0$10B$20B$30BQ4'22, Revenue: $19.9BQ4'22, Net income: $3.5BQ4'22Q1'23, Revenue: $20.9BQ1'23, Net income: −$68MQ1'23Q2'23, Revenue: $21.5BQ2'23, Net income: $5.1BQ2'23Q3'23, Revenue: $21.4BQ3'23, Net income: $26.0BQ3'23Q4'23, Revenue: $21.4BQ4'23, Net income: $4.0BQ4'23Q1'24, Revenue: $21.4BQ1'24, Net income: $3.3BQ1'24Q2'24, Revenue: $22.4BQ2'24, Net income: $4.7BQ2'24Q3'24, Revenue: $22.5BQ3'24, Net income: $2.7BQ3'24Q4'24, Revenue: $22.5BQ4'24, Net income: $3.4BQ4'24Q1'25, Revenue: $21.9BQ1'25, Net income: $11.0BQ1'25Q2'25, Revenue: $23.7BQ2'25, Net income: $5.5BQ2'25Q3'25, Revenue: $24.0BQ3'25, Net income: $5.2BQ3'25Q4'25, Revenue: $24.6BQ4'25, Net income: $5.1BQ4'25Q1'26, Revenue: $24.1BQ1'26, Net income: $5.2BQ1'26Q2'26, Revenue: $25.3BQ2'26, Net income: $5.5BQ2'26Q3'26, Revenue: $25.4BQ3'26, Net income: $210MQ3'26−$10B$0$10B$20B$30BQ4'22, Revenue: $19.9BQ4'22, Net income: $3.5BQ1'23, Revenue: $20.9BQ1'23, Net income: −$68MQ1'23Q2'23, Revenue: $21.5BQ2'23, Net income: $5.1BQ3'23, Revenue: $21.4BQ3'23, Net income: $26.0BQ3'23Q4'23, Revenue: $21.4BQ4'23, Net income: $4.0BQ1'24, Revenue: $21.4BQ1'24, Net income: $3.3BQ1'24Q2'24, Revenue: $22.4BQ2'24, Net income: $4.7BQ3'24, Revenue: $22.5BQ3'24, Net income: $2.7BQ3'24Q4'24, Revenue: $22.5BQ4'24, Net income: $3.4BQ1'25, Revenue: $21.9BQ1'25, Net income: $11.0BQ1'25Q2'25, Revenue: $23.7BQ2'25, Net income: $5.5BQ3'25, Revenue: $24.0BQ3'25, Net income: $5.2BQ3'25Q4'25, Revenue: $24.6BQ4'25, Net income: $5.1BQ1'26, Revenue: $24.1BQ1'26, Net income: $5.2BQ1'26Q2'26, Revenue: $25.3BQ2'26, Net income: $5.5BQ3'26, Revenue: $25.4BQ3'26, Net income: $210MQ3'26

Net income losses drawn in red.

Free cash flow
$0$3B$5B$8B$10BQ4'22, Free cash flow: $3.8BQ4'22Q1'23, Free cash flow: $2.4BQ1'23Q2'23, Free cash flow: $3.1BQ2'23Q3'23, Free cash flow: $6.5BQ3'23Q4'23, Free cash flow: $6.3BQ4'23Q1'24, Free cash flow: $2.9BQ1'24Q2'24, Free cash flow: $4.7BQ2'24Q3'24, Free cash flow: $7.0BQ3'24Q4'24, Free cash flow: $5.4BQ4'24Q1'25, Free cash flow: $3.4BQ1'25Q2'25, Free cash flow: $2.8BQ2'25Q3'25, Free cash flow: $8.0BQ3'25Q4'25, Free cash flow: $5.5BQ4'25Q1'26, Free cash flow: $1.5BQ1'26Q2'26, Free cash flow: $7.3BQ2'26Q3'26, Free cash flow: $6.4BQ3'26$0$3B$5B$8B$10BQ4'22, Free cash flow: $3.8BQ1'23, Free cash flow: $2.4BQ1'23Q2'23, Free cash flow: $3.1BQ3'23, Free cash flow: $6.5BQ3'23Q4'23, Free cash flow: $6.3BQ1'24, Free cash flow: $2.9BQ1'24Q2'24, Free cash flow: $4.7BQ3'24, Free cash flow: $7.0BQ3'24Q4'24, Free cash flow: $5.4BQ1'25, Free cash flow: $3.4BQ1'25Q2'25, Free cash flow: $2.8BQ3'25, Free cash flow: $8.0BQ3'25Q4'25, Free cash flow: $5.5BQ1'26, Free cash flow: $1.5BQ1'26Q2'26, Free cash flow: $7.3BQ3'26, Free cash flow: $6.4BQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$10B$20B$30B$40BQ4'22, Cash and equivalents: $12.9BQ4'22, Long-term debt: $26.9BQ4'22Q1'23, Cash and equivalents: $19.2BQ1'23, Long-term debt: $34.9BQ1'23Q2'23, Cash and equivalents: $21.2BQ2'23, Long-term debt: $33.9BQ2'23Q3'23, Cash and equivalents: $19.7BQ3'23, Long-term debt: $26.1BQ3'23Q4'23, Cash and equivalents: $21.9BQ4'23, Long-term debt: $25.9BQ4'23Q1'24, Cash and equivalents: $25.5BQ1'24, Long-term debt: $25.1BQ1'24Q2'24, Cash and equivalents: $24.9BQ2'24, Long-term debt: $31.6BQ2'24Q3'24, Cash and equivalents: $20.0BQ3'24, Long-term debt: $31.3BQ3'24Q4'24, Cash and equivalents: $24.1BQ4'24, Long-term debt: $30.7BQ4'24Q1'25, Cash and equivalents: $38.5BQ1'25, Long-term debt: $38.4BQ1'25Q2'25, Cash and equivalents: $18.6BQ2'25, Long-term debt: $39.2BQ2'25Q3'25, Cash and equivalents: $18.2BQ3'25, Long-term debt: $39.4BQ3'25Q4'25, Cash and equivalents: $19.7BQ4'25, Long-term debt: $39.4BQ4'25Q1'26, Cash and equivalents: $21.7BQ1'26, Long-term debt: $37.5BQ1'26Q2'26, Cash and equivalents: $20.4BQ2'26, Long-term debt: $37.3BQ2'26Q3'26, Cash and equivalents: $16.9BQ3'26, Long-term debt: $35.8BQ3'26$0$10B$20B$30B$40BQ4'22, Cash and equivalents: $12.9BQ4'22, Long-term debt: $26.9BQ1'23, Cash and equivalents: $19.2BQ1'23, Long-term debt: $34.9BQ1'23Q2'23, Cash and equivalents: $21.2BQ2'23, Long-term debt: $33.9BQ3'23, Cash and equivalents: $19.7BQ3'23, Long-term debt: $26.1BQ3'23Q4'23, Cash and equivalents: $21.9BQ4'23, Long-term debt: $25.9BQ1'24, Cash and equivalents: $25.5BQ1'24, Long-term debt: $25.1BQ1'24Q2'24, Cash and equivalents: $24.9BQ2'24, Long-term debt: $31.6BQ3'24, Cash and equivalents: $20.0BQ3'24, Long-term debt: $31.3BQ3'24Q4'24, Cash and equivalents: $24.1BQ4'24, Long-term debt: $30.7BQ1'25, Cash and equivalents: $38.5BQ1'25, Long-term debt: $38.4BQ1'25Q2'25, Cash and equivalents: $18.6BQ2'25, Long-term debt: $39.2BQ3'25, Cash and equivalents: $18.2BQ3'25, Long-term debt: $39.4BQ3'25Q4'25, Cash and equivalents: $19.7BQ4'25, Long-term debt: $39.4BQ1'26, Cash and equivalents: $21.7BQ1'26, Long-term debt: $37.5BQ1'26Q2'26, Cash and equivalents: $20.4BQ2'26, Long-term debt: $37.3BQ3'26, Cash and equivalents: $16.9BQ3'26, Long-term debt: $35.8BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 21, 2026.

Johnson & Johnson income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 27, 2026filed Oct 21, 2026Q2 FY2026ended Jun 28, 2026filed Jul 23, 2026Q1 FY2026ended Mar 29, 2026filed Apr 22, 2026Q4 FY2025ended Dec 28, 2025filed Feb 11, 2026Q3 FY2025ended Sep 28, 2025filed Oct 22, 2025Q2 FY2025ended Jun 29, 2025filed Jul 24, 2025Q1 FY2025ended Mar 30, 2025filed Apr 23, 2025Q4 FY2024ended Dec 29, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue25,39925,31024,06224,56423,99323,74321,89322,520+5.9%
Cost of revenue8,0978,0518,1067,9687,3037,6287,3577,128+10.9%
Gross profit17,30217,25915,95616,59616,69016,11514,53615,392+3.7%
Research and development—————————
Selling, general and administrative6,2856,4326,0346,7535,9225,8895,1126,453+6.1%
Operating income—————————
Other income (expense)(5,780)(331)(294)(483)478(107)7,321161−1309.2%
Pretax income346,7475,9904,9667,4936,49113,6313,887−99.5%
Income tax(176)1,213755(150)2,3419542,632456−107.5%
Net income2105,5345,2355,1165,1525,53710,9993,431−95.9%
Diluted EPS ($)0.092.272.14—2.122.294.54—−95.8%
Diluted shares (millions)2,4492,4402,445—2,4292,4192,424——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 21, 2026.

Johnson & Johnson balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 27, 2026filed Oct 21, 2026Q2 FY2026ended Jun 28, 2026filed Jul 23, 2026Q1 FY2026ended Mar 29, 2026filed Apr 22, 2026Q4 FY2025ended Dec 28, 2025filed Feb 11, 2026Q3 FY2025ended Sep 28, 2025filed Oct 22, 2025Q2 FY2025ended Jun 29, 2025filed Jul 24, 2025Q1 FY2025ended Mar 30, 2025filed Apr 23, 2025Q4 FY2024ended Dec 29, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents16,91020,42221,68819,70918,23118,57738,47424,105−7.2%
Short-term investments318336363393331303307417−3.9%
Total current assets56,35159,77459,17355,62454,61154,49871,55155,893+3.2%
Total assets197,425201,061200,894199,210192,816193,389193,671180,104+2.4%
Total current liabilities55,45754,89557,71654,12650,86954,18056,90350,321+9.0%
Long-term debt35,79937,34437,52739,43839,40839,23538,35530,651−9.2%
Total liabilities115,896116,090119,708117,666113,539114,916115,562108,614+2.1%
Stockholders’ equity81,52984,97181,18681,54479,27778,47378,10971,490+2.8%
Shares outstanding (millions)2,4072,4102,4072,4102,4092,4082,4062,408—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 21, 2026.

Johnson & Johnson cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 27, 2026filed Oct 21, 2026Q2 FY2026ended Jun 28, 2026filed Jul 23, 2026Q1 FY2026ended Mar 29, 2026filed Apr 22, 2026Q4 FY2025ended Dec 28, 2025filed Feb 11, 2026Q3 FY2025ended Sep 28, 2025filed Oct 22, 2025Q2 FY2025ended Jun 29, 2025filed Jul 24, 2025Q1 FY2025ended Mar 30, 2025filed Apr 23, 2025Q4 FY2024ended Dec 29, 2024filed Feb 13, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow7,7208,6162,5147,3099,1693,8784,1746,983−15.8%
Capital expenditures1,3621,3211,0491,8371,1571,0437951,612+17.7%
Free cash flow (CFO − capex)6,3587,2951,4655,4728,0122,8353,3795,371−20.6%
Depreciation and amortization2,1171,9592,0042,0111,7771,9431,7721,896+19.1%
Share repurchases1,7092214,0281,9241,90202,127282−10.1%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 11, 2026.

Income statement

Johnson & Johnson income statement, annual
Millions of dollarsFY2025ended Dec 28, 2025filed Feb 11, 2026FY2024ended Dec 29, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Jan 1, 2023filed Feb 16, 2023FY2021ended Jan 2, 2022filed Feb 17, 2022FY2020ended Jan 3, 2021filed Feb 22, 2021FY2019ended Dec 29, 2019filed Feb 18, 2020FY2018ended Dec 30, 2018filed Feb 20, 2019FY2017ended Dec 31, 2017filed Feb 21, 2018FY2016ended Jan 1, 2017filed Feb 27, 2017FY2015ended Jan 3, 2016filed Feb 24, 2016FY2014ended Dec 28, 2014filed Feb 24, 2015FY2013ended Dec 29, 2013filed Feb 21, 2014FY2012ended Dec 30, 2012filed Feb 22, 2013FY2011ended Jan 1, 2012filed Feb 23, 2012FY2010ended Jan 2, 2011filed Feb 25, 2011FY2009ended Jan 3, 2010filed Mar 1, 2010FY2008ended Dec 28, 2008filed Aug 4, 2009FY2007ended Dec 30, 2007filed Aug 4, 2009
Revenue94,19388,82185,15979,99078,74082,58482,05981,58176,45071,890—————————
Cost of revenue30,25627,47126,55324,59623,40228,42727,55627,09125,439——————————
Gross profit63,93761,35058,60655,39455,33854,15754,50354,49051,01150,10148,53851,58548,97045,56644,67042,79543,45045,23643,344
Research and development1091,84148300——————————————
Selling, general and administrative23,67622,86921,51220,24620,11822,08422,17822,54021,52020,06721,20321,95421,83020,86920,96919,42419,80121,49020,451
Operating income———————————21,59016,41214,95513,76517,70016,582——
Other income (expense)7,209(4,694)(6,634)(810)(526)(2,899)(2,525)(1,405)42(210)2,06470(2,498)(1,626)(2,743)7685261,015(534)
Pretax income32,58116,68715,06219,35919,17816,49717,32817,99917,67319,80319,19620,56315,47113,77512,36116,94715,75516,92913,283
Income tax5,7772,6211,7362,9891,3771,7832,2092,70216,3733,2633,7874,2401,6403,2612,6893,6133,4893,9802,707
Net income26,80414,06635,15317,94120,87814,71415,11915,2971,30016,54015,40916,32313,83110,8539,67213,334———
Diluted EPS ($)11.035.7913.726.737.815.515.635.610.475.935.485.704.813.863.494.784.404.573.63
Diluted shares (millions)2,4292,4292,5602,6642,6742,6712,6842,7292,7452,7892,8132,8642,8772,8132,7752,7892,7892,8362,911

Balance sheet

Johnson & Johnson balance sheet, annual
Millions of dollarsFY2025ended Dec 28, 2025filed Feb 11, 2026FY2024ended Dec 29, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Jan 1, 2023filed Feb 16, 2023FY2021ended Jan 2, 2022filed Feb 17, 2022FY2020ended Jan 3, 2021filed Feb 22, 2021FY2019ended Dec 29, 2019filed Feb 18, 2020FY2018ended Dec 30, 2018filed Feb 20, 2019FY2017ended Dec 31, 2017filed Feb 21, 2018FY2016ended Jan 1, 2017filed Feb 27, 2017FY2015ended Jan 3, 2016filed Feb 24, 2016FY2014ended Dec 28, 2014filed Feb 24, 2015FY2013ended Dec 29, 2013filed Feb 21, 2014FY2012ended Dec 30, 2012filed Feb 22, 2013FY2011ended Jan 1, 2012filed Feb 23, 2012FY2010ended Jan 2, 2011filed Feb 25, 2011FY2009ended Jan 3, 2010filed Mar 1, 2010FY2008ended Dec 28, 2008filed Aug 4, 2009FY2007ended Dec 30, 2007filed Aug 4, 2009
Cash and equivalents19,70924,10521,85912,88914,48713,98517,30518,10717,82418,97213,73214,52320,92714,91124,54219,35515,81010,7687,770
Short-term investments3934171,0689,39217,12111,2001,9821,58047222,93524,64418,566———————
Total current assets55,62455,89353,49555,29460,97951,23745,27446,03343,08865,03260,21055,74456,40746,11654,31647,30739,54134,377—
Total assets199,210180,104167,558187,378182,018174,894157,728152,954157,303141,208133,411130,358132,683121,347113,644102,90894,68284,912—
Total current liabilities54,12650,32146,28255,80245,22642,49335,96431,23030,53726,28727,74725,03125,67524,26222,81123,07221,73120,852—
Long-term debt39,43830,65125,88126,88629,98532,63526,49427,68430,67522,44212,85715,12213,32811,48912,9699,1568,2238,120—
Total liabilities117,666108,61498,784110,574107,995111,61698,25793,20297,14370,79062,26160,60658,63056,52156,56446,32944,09442,401—
Stockholders’ equity81,54471,49068,77476,804———————————————
Shares outstanding (millions)2,4102,4082,4092,6042,6292,6292,6352,6632,6832,7132,7592,7802,8292,7952,7452,7352,752——

Cash flow statement

Johnson & Johnson cash flow statement, annual
Millions of dollarsFY2025ended Dec 28, 2025filed Feb 11, 2026FY2024ended Dec 29, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 16, 2024FY2022ended Jan 1, 2023filed Feb 16, 2023FY2021ended Jan 2, 2022filed Feb 17, 2022FY2020ended Jan 3, 2021filed Feb 22, 2021FY2019ended Dec 29, 2019filed Feb 18, 2020FY2018ended Dec 30, 2018filed Feb 20, 2019FY2017ended Dec 31, 2017filed Feb 21, 2018FY2016ended Jan 1, 2017filed Feb 27, 2017FY2015ended Jan 3, 2016filed Feb 24, 2016FY2014ended Dec 28, 2014filed Feb 24, 2015FY2013ended Dec 29, 2013filed Feb 21, 2014FY2012ended Dec 30, 2012filed Feb 22, 2013FY2011ended Jan 1, 2012filed Feb 23, 2012FY2010ended Jan 2, 2011filed Feb 25, 2011FY2009ended Jan 3, 2010filed Mar 1, 2010FY2008ended Dec 28, 2008filed Aug 4, 2009FY2007ended Dec 30, 2007filed Aug 4, 2009
Operating cash flow24,53024,26622,79121,19423,41023,53623,41622,20121,05618,76719,56918,71017,41415,39614,29816,38516,57114,97215,022
Capital expenditures4,8324,4244,5434,0093,6523,3473,4983,6703,2793,2263,4633,7143,5952,9342,8932,3842,3653,0662,942
Free cash flow (CFO − capex)19,69819,84218,24817,18519,75820,18919,91818,53117,77715,54116,10614,99613,81912,46211,40514,00114,20611,90612,080
Depreciation and amortization7,5037,3397,4866,9707,3907,2317,0096,9295,6423,7543,7463,8954,1043,6663,1582,9392,7742,8322,777
Share repurchases5,9532,4325,0546,0353,4563,2216,7465,8686,3588,9795,2907,1243,53812,9192,5252,7972,1306,6515,607
Dividends paid———————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$62M
9 sales by 4 insiders; officers and directors $62M
Bought, twelve months
$258K
1 purchases by 1 insider; officers and directors $258K
Sold, twelve months
$151M
28 sales by 10 insiders; officers and directors $151M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechoption exercise11,070$131.94$1M36,517Sep 4, 2026
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechopen-market sale11,070$274.74$3M25,447Sep 4, 2026
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechoption exercise22,527$151.41$3M47,974Sep 4, 2026
Sep 2, 2026Schmid TimothyEVP, WW Chair, MedTechopen-market sale22,527$274.74$6M25,447Sep 4, 2026
Aug 17, 2026Taubert Jennifer LEVP, WWC. Innovative Medicineoption exercise15,000$115.67$2M209,451Aug 18, 2026
Aug 17, 2026Taubert Jennifer LEVP, WWC. Innovative Medicineopen-market sale15,000$263.36$4M194,451Aug 18, 2026
Aug 13, 2026Duato JoaquinCEO and Chairman of the Board, Directoroption exercise123,291$115.67$14M399,258Aug 14, 2026
Aug 13, 2026Duato JoaquinCEO and Chairman of the Board, Directoropen-market sale20,976$262.00$5M378,282Aug 14, 2026
Aug 13, 2026Duato JoaquinCEO and Chairman of the Board, Directoropen-market sale102,315$261.00$27M275,967Aug 14, 2026
Aug 6, 2026Forminard ElizabethEVP, Chief Legal Officeroption exercise9,344$131.94$1M32,912Aug 7, 2026
Aug 6, 2026Forminard ElizabethEVP, Chief Legal Officeropen-market sale9,344$257.75$2M23,568Aug 7, 2026
Aug 6, 2026Forminard ElizabethEVP, Chief Legal Officeropen-market sale6,574$255.93$2M16,994Aug 7, 2026
Aug 5, 2026Duato JoaquinCEO and Chairman of the Board, Directoropen-market sale41,957$258.06$11M282,490Aug 7, 2026
Aug 5, 2026Duato JoaquinCEO and Chairman of the Board, Directoropen-market sale6,523$258.74$2M275,967Aug 7, 2026
Jul 20, 2026Broadhurst VanessaEVP, Global Corp Affairsoption exercise11,129$129.51$1M34,132Jul 21, 2026
Jul 20, 2026Broadhurst VanessaEVP, Global Corp Affairsoption exercise11,925$131.94$2M46,057Jul 21, 2026
Jul 20, 2026Broadhurst VanessaEVP, Global Corp Affairsopen-market sale23,054$251.27$6M23,003Jul 21, 2026
Jun 11, 2026Wengel Kathryn EEVP, Chief TO and Risk Officeroption exercise10,000$115.67$1M124,288Jun 12, 2026
Jun 11, 2026Wengel Kathryn EEVP, Chief TO and Risk Officeropen-market sale10,000$241.15$2M114,288Jun 12, 2026
May 1, 2026Reed John CEVP, Innovative Medicine, R&Doption exercise25,255$0.00—35,913May 4, 2026
May 1, 2026Reed John CEVP, Innovative Medicine, R&Dtax withholding11,002$229.85$3M24,911May 4, 2026
Feb 27, 2026Decker Robert JVP Corporate Controlleropen-market sale4,075$247.87$1M23,682Mar 3, 2026
Feb 27, 2026Decker Robert JVP Corporate Controlleroption exercise4,075$115.67$471K27,757Mar 3, 2026
Feb 20, 2026Schmid TimothyEVP, WW Chair, MedTechopen-market sale1,322$245.66$325K25,447Feb 23, 2026
Feb 18, 2026Schmid TimothyEVP, WW Chair, MedTechopen-market sale8,998$244.53$2M26,769Feb 18, 2026

Full insider history for Johnson & Johnson, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held JNJ in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded JNJ by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$6M25,1720.01%added +11.9%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
Johnson & Johnson, CIK 200406 on EDGAR
Extract generated
October 22, 2026
Withheld
3 line-years whose four quarters do not sum to the filed year: other income FY2009, cost of revenue FY2022, opex sga FY2022
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated October 22, 2026.

JSON file
/data/financials/JNJ.json